Valence Life Sciences

Valence Life Sciences

Valence Life Sciences is a New York-based private equity firm focused exclusively on life sciences, deploying capital across venture and growth-stage companies that integrate AI-driven discovery with therapeutic development. The firm operates at the convergence of biology and computation, targeting platform technologies rather than traditional drug development assets. The firm's strategy covers venture (general) and expansion-stage investments, with a mandate spanning biotech, health-tech, and AI/ML-enabled drug discovery. Confirmed investment areas include AI-native drug discovery platforms, digital biomarkers, and clinical-trial-enabling infrastructure — a mix that places Valence closer to tools-and-platforms investors like Lux Capital than to traditional biotech VCs. The firm invests primarily in North America, with potential exposure to European cross-border deals given sector dynamics. Team size and AUM are not publicly disclosed, reflecting a deliberate low-profile operational stance common among specialist health-tech funds. Without a public LinkedIn presence or widely reported fundraising events, the firm likely operates with a concentrated partner group rather than a distributed analyst team — a structure consistent with calibrated-velocity investment models in technical fields. What structurally differentiates Valence is its computational-first thesis in an industry still dominated by chemistry-first investing. By targeting platform companies that use AI to compress discovery timelines, the firm positions itself ahead of the adoption curve that larger pharmaceutical companies are only now beginning to internalize.